InTouch Indexed in Medline and Index Medicus

Publication
Article
OncologyONCOLOGY Vol 16 No 6
Volume 16
Issue 6

InTouch magazine, a sister publication of ONCOLOGY and Oncology News International, has been selected by the National Library of Medicine to be indexed and included in Index Medicus and Medline. InTouch is published by PRR for cancer patients and their families.

InTouch magazine, a sister publicationof ONCOLOGY and Oncology News International, has been selected by the NationalLibrary of Medicine to be indexed and included in Index Medicus and Medline. InTouch is published by PRR for cancer patients and their families.

"It’s a real tribute to the editorial quality of InTouch," said Steven T. Rosen, MD. Dr. Rosen, director of the Robert H.Lurie Comprehensive Cancer Center, serves as medical editor-in-chief for InTouch,which just celebrated its third year of publication.

The National Library of Medicine looks to an advisorycommittee—the Literature Selection Technical Review Committee—to choosejournals and other publications for citation. Composed of authoritiesknowledgeable in the field of biomedicine, the committee includes physicians,researchers, educators, editors, health science librarians, and historians whoreview and recommend titles for indexing. The databases in the Medlars system inwhich InTouch will appear are Index Medicus and Medline. These databases areavailable online internationally.

"We’re delighted that the NLM has recognized the integrity and valueof the information in InTouch," said Dr. Rosen. "Their endorsementfurthers our mission, which is to give patients and their loved ones the mostauthoritative and up-to-date information on cancer prevention and treatment sothat they can be better informed about their health care."

Recent Videos
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Patients with cancer are subjected to fewer radiotherapy-induced toxicities because of newer, more advanced technologies.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.
Related Content